Heuzé-Vourc’h, NathalieBioMed CentralCritical CareGuillon, A., Reckamp, K. L. & Heuze-Vourc'h, N. Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines? Crit. Care 21, 18 (2017)....
With the approval of the antiangiogenic antibody bevacizumab in non-small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second-line therapies have the potential to improve overall survival and quality of life over best supportive...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer Overall survival in metastatic non-small cell lung cancer is improved by immunotherapy but individual responses widely vary, and pre...
Such as lung cancer3, pancreatic cancer4, medulloblastoma5, and etc. it had emerged as an invaluable treatment option for many patients with HCC6,7. However, they were not successful in all patients. Despite these advances in the understanding of treatment strategy, the key molecules that ...
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-1571. doi:10.1016/S0140-6736(13)62159-5 PubMedGoogle ScholarCrossref 16. McGuinness LA, Higgins JPT. Risk-of-bias ...
Encephalitis Related to Immunotherapy for Lung Cancer: Analysis of a Multicenter Cohort. Lung Cancer 2020, 143, 36–39. [Google Scholar] [CrossRef] Müller-Jensen, L.; Zierold, S.; Versluis, J.M.; Boehmerle, W.; Huehnchen, P.; Endres, M.; Mohr, R.; Compter, A.; Blank, C.U....
Clinical/translational cancer immunotherapy: Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer 23 October 2024 Position article and guidelines: Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Ca...
Imfinzi (durvalumab). (2018, February). IMFINZI Is Now Approved for Unresectable Stage 3 Lung Cancer Following Chemoradiation Therapy.https://www.imfinzi.com/stage-3-nsclc.html Harris, J. (2017, July 27). Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial.https://www...
Single-cell tumor-infiltrating immune cell atlas from 13 cancer types [21] was used to visualize target gene expression. To evaluate expression in our previously published GC dataset [18], we reference mapped T and NK cells to the tumor-infiltrating immune cell atlas as outlined above. For vis...